AI Article Synopsis
- Rioprostil (600 micrograms daily) and ranitidine (150 mg daily) were compared for preventing duodenal ulcer recurrence over 6 months among 207 patients.
- The relapse rates were 14.9% for rioprostil and 10.1% for ranitidine, indicating similar effectiveness.
- Diarrhea was reported in 7 patients on rioprostil versus 3 on ranitidine, suggesting a slight increase in side effects with rioprostil.
Article Abstract
The efficacy of Rioprostil (a new prostaglandin E1 analogue) is compared with that of ranitidine in the recurrence prevention of duodenal ulcer(s). Duration of treatment is 6 months. Ninety-seven patients received rioprostil, 600 micrograms once-daily orally, and 110 patients received ranitidine, 150 mg once-daily orally. On rioprostil, 14.9% of patients showed a relapse after 6 months compared to 10.1% on ranitidine. Diarrhoea occurred in 7 patients on rioprostil and 3 patients on ranitidine. Rioprostil given 600 micrograms daily in the evening is a highly effective treatment for the prevention of duodenal ulcer relapse, the efficacy not being significantly different from ranitidine 150 mg.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365528909091205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!